AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax, Elevar Therapeutics - LARVOL DELTA

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Colorectal Cancer • Oncology • Rectal Cancer • Solid Tumor

SYSKY-2022-516: A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs (clinicaltrials.gov) - P2 | N=37 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Gallbladder Cancer • Oncology • Solid Tumor

Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Anti-Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single-Arm Meta-Analysis. (PubMed, Cancer Med) - "The combination shows promising antitumor activity and a generally acceptable safety profile in R/M NPC, particularly for immunotherapy-naive patients. These findings support further investigation in well-designed randomized controlled trials, but confirmation of its role relative to standard therapies requires larger comparative studies."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Dermatology • Hypertension • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study. (PubMed, J Chemother) - "No statistically significant differences in survival were detected among sintilimab, camrelizumab, and pembrolizumab. Grade 3-4 adverse events were comparable. Adding PD-1 blockade was associated with longer OS without substantially increasing severe toxicity."

Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Real-world effectiveness and safety of camrelizumab plus platinum and taxane as first-line treatment for advanced esophageal squamous cell carcinoma (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: 4-year follow-up from a phase 2 trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Real-World Effectiveness of Camrelizumab Plus Rivoceranib in Unresectable Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor

Transarterial chemoembolization (TACE) combined with Camrelizumab and Apatinib versus camrelizumab and apatinib in the treatment of unresectable hepatocellular carcinoma : A multicenter, open-label, randomized trial (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

A Multicenter, Randomized, Controlled Phase II Study of Camrelizumab Combined with Apatinib as Adjuvant Therapy in Patients with High Recurrence Risk After Radical Resection of Hepatocellular Carcinoma (ESMO 2026) - No abstract available

Clinical • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Hepatic arterial infusion chemotherapy combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus: A prospective single-arm study (ESMO 2026) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

First-Line Gemcitabine and Cisplatin Plus Camrelizumab and Apatinib in Nasopharyngeal Carcinoma with Liver Metastasis: Interim Analysis (ESMO 2026) - No abstract available

Clinical • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Liposomal irinotecan Ⅱ combined with gemcitabine, cisplatin and camrelizumab in the treatment of patients with unresectable biliary tract cancer (ESMO 2026) - No abstract available

Clinical • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Camrelizumab Plus Apatinib Combined with Gemcitabine and Oxaliplatin (GEMOX) as First-Line Treatment for Advanced Biliary Tract Cancer (BTC): A Biomarker Exploratory Phase II Trial (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • P2 data • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Bipolar androgen therapy sequential rezvilutamide combined with camrelizumab for patients with mCRPC: A single-arm prospective clinical study (ESMO 2026) - No abstract available

Clinical • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Camrelizumab Plus Apatinib for Locally Advanced or Metastatic Malignant Ocular Adnexal Tumors: A Multicenter, Multi-cohort, Single-arm Phase II Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ocular Melanoma • Oncology

Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: a prospective phase II clinical study (EANO 2026) - P2 | "Camrelizumab in combination with apatinib neoadjuvant therapy showed excellent efficacy in recurrent high-grade gliomas, and was superior to PD1 inhibitor monotherapy neoadjuvant treatment in rGBM patients."

Clinical • Combination therapy • P2 data • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Glioma • Gliosarcoma • High Grade Glioma • Oligodendroglioma • Oncology • Sarcoma • Solid Tumor • KDR

Clinical activity of chidamide-containing regimens after prior PD-1-based therapy in two patients with microsatellite-stable metastatic colorectal cancer: a case series and narrative review. (PubMed, Front Oncol) - "Case 1: A 60-year-old woman with BRAF V600E-mutant, right-sided, MSS mCRC received third-line surufatinib plus camrelizumab, with a best response of stable disease (SD) and a progression-free survival (PFS) of 5 months...Case 2: A 43-year-old man with recurrent RAS/BRAF wild-type MSS mCRC received fifth-line surufatinib plus sintilimab (PR, PFS 8.5 months) and, after progression, seventh-line chidamide plus sintilimab plus bevacizumab (SD, PFS 5.5 months)...As descriptive observations, these findings are hypothesis-generating only and are insufficient to demonstrate reversal of immunotherapy resistance or survival benefit. Prospective biomarker-driven studies are warranted to evaluate epigenetic-immunotherapy combinations in this subgroup."

IO biomarker • Journal • Colorectal Cancer • Gene Therapies • Oncology • Solid Tumor • BRAF

Real-World Comparative Effectiveness of Four Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (IASLC-WCLC 2026) - "Conclusions : In this real-world cohort of advanced lung cancer, camrelizumab, pembrolizumab, sintilimab, and tislelizumab demonstrated distinct effectiveness under several specific circumstances. Both PD-L1 expression pattern and histologic subtype may influence the relative clinical benefit and prognosis associated with different ICIs."

Checkpoint inhibition • Clinical • HEOR • IO biomarker • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Predictive Model for First-Line Chemo-Immunotherapy in Driver-Negative Lung Adenocarcinoma With Brain Metastases (IASLC-WCLC 2026) - "Immune checkpoint inhibitors (ICIs) included tislelizumab (n=20), pembrolizumab (n=18), camrelizumab (n=17), sintilimab (n=15), toripalimab (n=5), and durvalumab (n=1), all administered in combination with chemotherapy. Conclusions : A prediction model incorporating Ki-67, PD-L1, NLR, and neurologic symptoms demonstrated strong discriminative ability for estimating systemic response to first-line chemo-immunotherapy in LUAD-BM. DoR was associated with PFS, whereas TTR was not, indicating that the maintenance of tumor response rather than early response onset may be more relevant to long-term outcomes."

Clinical • Predictive model • Brain Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Association of Early Versus Late Time of Day Immune Checkpoint Inhibitors Administration With Survival Outcomes in Gastric and Esophageal Cancers: A Meta-Analytical Evaluation (ACG 2026) - "Eligible studies included patients with advanced gastric or esophageal cancer treated with ICIs, including nivolumab, pembrolizumab, sintilimab, camrelizumab, tislelizumab, toripalimab, and durvalumab, administered either as monotherapy or in combination with chemotherapy. A total of 702 patients were included, comprising 520 patients with gastric cancer and 182 patients with esophageal cancer. In gastric cancer, early ICI administration was associated with significantly improved OS (pooled HR, 0.61; 95% CI, 0.49â0.77) and PFS (pooled HR, 0.62; 95% CI, 0.43â0.89). In esophageal cancer, early administration was associated with improved PFS (pooled HR, 0.40; 95% CI, 0.22â0.72)."

Checkpoint inhibition • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor

Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma (clinicaltrials.gov) - P2 | N=138 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Head and Neck Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis. (PubMed, J Gastrointest Oncol) - "For OS, TACE + anlotinib + sintilimab (TACE + Anl + Sin), TACE + donafenib + toripalimab (TACE + Don + Tor), TACE + lenvatinib + tislelizumab (TACE + Len + Tis), TACE + sorafenib + camrelizumab (TACE + Sor + Cam), and TACE + apatinib + camrelizumab (TACE + Apa + Cam) were all significantly superior to TACE alone...For PFS, compared with TACE alone, TACE + Anl + Sin, TACE + Don + Tor, TACE + lenvatinib + pembrolizumab (TACE + Len + Pem), TACE + Len + Tis, and TACE + Apa + Cam significantly prolonged PFS...For DCR, TACE + Len + Tis showed the best performance, while TACE + atezolizumab + bevacizumab (TACE + Ate + Bev), TACE + Anl + Sin, and TACE + Apa + Cam also demonstrated relatively high DCR. Compared with TACE alone, TACE combined with MTAs and ICIs can significantly improve outcomes in patients with uHCC. TACE + Anl + Sin, TACE + Len + Tis, and TACE + Apa + Cam may be promising treatment options, although more prospective studies are needed for further validation."

Checkpoint inhibition • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation-negative non-squamous NSCLC in China: a cost-effectiveness analysis. (PubMed, Front Pharmacol) - "The network meta-analysis demonstrated that toripalimab, sintilimab, and pembrolizumab combined with chemotherapy provided superior efficacy and favorable safety among 13 PD-1/PD-L1 inhibitors with chemotherapy for non-sqNSCLC...Compared with chemotherapy alone, camrelizumab, tislelizumab, sintilimab with chemotherapy were cost-effective, with ICERs of $28,813.78/QALY, $19,278.47/QALY, and $20,315.01/QALY, respectively...Among currently available first-line treatment strategies for driver mutation-negative non-sqNSCLC in China, toripalimab and sintilimab combined with chemotherapy demonstrated favorable clinical and economic profiles. These findings provide evidence to support treatment selection, reimbursement decisions, and healthcare resource allocation in clinical practice."

HEOR • IO biomarker • Journal • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review. (PubMed, Front Oncol) - "Unlike previously reported eyelid lesions requiring excision, conservative management with topical levofloxacin resulted in complete lesion resolution within four weeks without discontinuation of systemic therapy (Naranjo score: 7). This represents the first documented case of RCCEP affecting the conjunctival mucosa. It underscores the necessity of ophthalmologic surveillance in patients receiving camrelizumab and demonstrates that topical antimicrobial therapy constitutes an effective therapeutic strategy for complicated ocular RCCEP."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Infectious Disease • Oncology • Ophthalmology • Squamous Cell Carcinoma